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Background: To identify the determinants of successful antiretroviral (ARV) therapy, researchers study the virological
responses to treatment-change episodes (TCEs) accompanied by baseline plasma HIV-1 RNA levels, CD4+ T
lymphocyte counts, and genotypic resistance data. Such studies, however, often differ in their inclusion and
virological response criteria making direct comparisons of study results problematic. Moreover, the absence of a
standard method for representing the data comprising a TCE makes it difficult to apply uniform criteria in the
analysis of published studies of TCEs.
Results: To facilitate data sharing for TCE analyses, we developed an XML (Extensible Markup Language) Schema
that represents the temporal relationship between plasma HIV-1 RNA levels, CD4 counts and genotypic drug
resistance data surrounding an ARV treatment change. To demonstrate the adaptability of the TCE XML Schema to
different clinical environments, we collaborate with four clinics to create a public repository of about 1,500 TCEs.
Despite the nascent state of this TCE XML Repository, we were able to perform an analysis that generated a novel
hypothesis pertaining to the optimal use of second-line therapies in resource-limited settings. We also developed
an online program (TCE Finder) for searching the TCE XML Repository and another program (TCE Viewer) for
generating a graphical depiction of a TCE from a TCE XML Schema document.
Conclusions: The TCE Suite of applications – the XML Schema, Viewer, Finder, and Repository – addresses several
major needs in the analysis of the predictors of virological response to ARV therapy. The TCE XML Schema and
Viewer facilitate sharing data comprising a TCE. The TCE Repository, the only publicly available collection of TCEs,
and the TCE Finder can be used for testing the predictive value of genotypic resistance interpretation systems and
potentially for generating and testing novel hypotheses pertaining to the optimal use of salvage ARV therapy.
Keywords: Human immunodeficiency virus, Antiretroviral treatment, Drug resistance, Clinical outcomes, XML
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To identify determinants of successful antiretroviral (ARV)
therapy in HIV-1-infected patients for whom a previous
ARV treatment regimen has failed, researchers study clin-
ical data associated with treatment-change episodes (TCEs)
[1]. These studies characterize the relationship between past
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reproduction in any medium, provided the orresistance genotype results, and the subsequent virological
response to a salvage therapy regimen [2-8]. Such studies,
however, often differ in their inclusion criteria, salvage ther-
apy requirements, and definition of virological response.
To facilitate data sharing and analyses of combined
data, we have developed a TCE XML Schema to repre-
sent treatment-change episodes. XML (Extensible
Markup Language) is a markup language for encoding
human and computer readable documents. An XML
Schema defines constrained elements and attributes that
can ensure a consistent representation of complex data.
The TCE XML Schema is a richer representation of datad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for most analyses [9]. Here we collaborate with four clinics
to create a public repository of 1,500 TCE XML documents
represented using the TCE XML Schema (TCE Repository).
To demonstrate the utility of such a repository for hypoth-
esis generation and knowledge discovery, we analyzed a sub-
set of the repository to obtain insights into the optimal use
of second-line therapy in resource-limited settings.
We also describe two online programs that complement
the TCE XML Schema: a TCE Viewer and a TCE Finder.
The TCE Viewer accepts a valid TCE XML Schema docu-
ment and creates a graphical depiction of the temporal re-
lationship between ARV regimens, plasma HIV-1 RNA
levels, peripheral blood CD4+ T lymphocyte counts (CD4
counts), and genotypic resistance data. The TCE Finder
searches the TCE Repository according to user-defined cri-
teria and retrieves those that meet the search criteria.
Methods
TCE XML schema
The TCE XML Schema elements and constraints were
developed to represent the temporal relationship among
ARVs, plasma HIV-1 RNA levels, CD4 counts and geno-
typic drug resistance data surrounding a treatment
change. Each valid TCE XML Schema document must
have a treatment change time point (baseline or time
zero). The TCE baseline must be assigned a date or, at
the very minimum, a calendar year. The preceding and
subsequent data are demarcated by the number of weeks
from baseline. The complete treatment history received
before baseline is represented as a list of regimens, their
durations, and associated plasma HIV-1 RNA levels and
CD4 counts. However, if these data are not available, the
XML Schema can represent the past treatment history as
a list of one or more ARVs or ARV classes. Genotypic
drug resistance test results are represented as nucleotide
sequences or lists of amino acid mutations obtained
prior to the treatment change. Optional elements include
the nadir CD4 count, gender, age, ethnicity, and a meta-
data element for either annotating or just naming the
TCE. The TCE XML Schema can be found at http://
hivdb.stanford.edu/TCEs/schema/TCE.xsd.
To demonstrate the adaptability of the TCE XML
Schema to different clinical environments, we collabo-
rated with four clinics from Kaiser-Permanente Medical
Care Program-Northern/Southern California, University
of Barcelona and EuResist Network Database. The study
was approved by the Stanford University Institutional
Review Board (“Clinical Significance of HIV-1 Drug Re-
sistance: A Clinic Based Approach”, Protocol ID: 13900).
TCE viewer
The TCE Viewer creates a graphical depiction of a TCE
(http://hivdb.stanford.edu/TCEs/cgi-bin/TCE_viewer.cgi).The TCE Viewer accepts an XML file, validates the file
against the TCE Schema, and generates a graphical de-
piction of the TCE containing three sections: (i) a figure
with the ARV regimens, plasma HIV-1 RNA levels, and
CD4 counts preceding and following the treatment
change; (ii) a table with one or more genotypic resistance
test results preceding the treatment change; and (iii) a
compressed summary of the virological and immuno-
logical responses to past ARV regimens. The TCE
Viewer provides an additional mechanism of validation
because many clinicians are adept at visually recognizing
anomalous clinical patterns that may have resulted from
data entry errors.
TCE finder
The TCE Finder enables users to identify TCEs meeting
user-defined search criteria (http://hivdb.stanford.edu/
TCEs/cgi-bin/TCE_finder.cgi). The TCE Finder accepts in-
put parameters pertaining to the ARVs used prior to the
change in therapy and/or to the ARVs used for salvage
therapy. A summary of the TCEs matching the input cri-
teria are then presented to the user in a table that contains
the following fields: ARVs received and genotypic resistance
test results obtained prior to baseline, the salvage ARV regi-
men, and plasma HIV-1 RNA levels obtained while taking
the salvage ARV regimen. The table also contains a thumb-
nail image of each TCE that links to the graphical depiction
of the TCE created by the TCE Viewer.
Results
TCE repository
To demonstrate the ability of the TCE Schema to represent
data from different clinics, we collaborated with four clinics
to create a publicly available TCE repository. For the pur-
poses of our collaboration we selected TCEs sharing each
of the following criteria: (i) evidence for virological failure
prior to a change in therapy defined a plasma HIV-1 RNA
level of >1,000 copies/ml obtained within 8 weeks before
the change; (ii) a complete list of ARVs received prior to
baseline; (iii) a change in ARVs occurring within 24 weeks
of a baseline genotypic resistance test; (iv) a new salvage
regimen administered for at least four weeks; (v) one or
more CD4 counts within 24 weeks prior to the ARV
change; and (vi) two or more plasma HIV-1 RNA levels
within the first 36 weeks while taking the salvage regimen.
Overall, 1,527 TCEs met the above inclusion criteria in-
cluding 1,217 from Northern California, 162 from the Uni-
versity of Barcelona, 90 from Southern California and 58
from the EuResist Network Database. The TCEs occurred
between 1998 and 2010: 555 between 1998 and 2000; 550
between 2001 and 2003; 228 between 2004 and 2006; 195
between 2007 and 2010. The median CD4 nadir was 108
(IQR: 34 to 213). The median plasma HIV-1 RNA levels
and CD4 counts were 4.2 log copies/ml (IQR: 3.7 to 4.7)
Table 2 Summary of the ARV Class Combinations
Comprising the Salvage ARV Regimens
Type 1 Regimens
NRTIs, NNRTIs, and/or PIs
Type 2 Regimens
Raltegravir (RAL), enfuvirtide (ENF),
and/or Maraviroc (MVC)
ARV Class Combination No. TCE ARV Class Combination No. TCE
2 NRTIs + PI/r 364 ≥1NRTI + PI/r + RAL 37
≥3 NRTIs + PI/r 194 ≥1NRTI + PI/r + ENF 30
2 NRTIs + NNRTI 149 ≥1NRTI + NNRTI + PI/r + RAL 13
1 NRTI + NNRTI + PI/r 102 ≥1NRTI + NNRTI + PI/r + ENF 7
2 NRTIs + NNRTI + PI/r 90 ≥1NRTI + RAL 7
2 NRTIs + PI 90 ≥1NRTI + PI/r + RAL + ENF 6
≥3 NRTIs + NNRTI 79 PI/r + RAL 5
≥3 NRTIs 62 PI/r + RAL +MVC 5
1 NRTI + NNRTI + PI 49 ≥1NRTI + NNRTI + RAL 4
1 NRTI + PI/r 45 ≥1NRTI + PI/r + RAL +MVC 4
2 NRTIs + NNRTI + PI 44 ≥1NRTI + RAL +MVC 4
≥3 NRTIs + PI 36 NNRTI + PI/r + RAL 3
≥3 NRTIs + NNRTI + PI/r 25 ≥1NRTI + NNRTI + PI + ENF 2
NNRTI + PI 19 ≥1NRTI + NNRTI + RAL + ENF 2
≥3 NRTIs + NNRTI + PI 9 ≥1NRTI + PI/r +MVC 2
PI/r 3 ≥1NRTI + PI/r +MVC+ ENF 2
NNRTI + RAL +MVC 2
Miscellaneous 22 Miscellaneous 10
Total 1,382 Total 145
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received a median six years (IQR: 3 to 8) of ARV therapy
prior to the TCE. Previous ARVs included a median of four
NRTIs, two PIs, and one NNRTI.
A complete listing of the ARVs used in the salvage regi-
mens is shown in Table 1. Table 2 summarizes the ARV
class combinations comprising the salvage therapy regi-
mens: (i) 1,382 regimens (denoted in Table 2 as Type 1 regi-
mens) comprised combinations of the first three approved
ARV classes: NRTIs, NNRTIs, and PIs; (ii) 145 regimens
(denoted in Table 2 as Type 2 regimens) contained at least
one of the newer classes including the integrase inhibitor,
raltegravir (RAL), fusion inhibitor, enfurvirtide (ENF), and
CCR5 antagonist, maraviroc (MVC).
The median duration of the salvage therapy regimen was
52 weeks (IQR: 38 to 52). Plasma HIV-1 RNA levels follow-
ing the ARV change were available a median of every
13 weeks. One or more plasma HIV-1 RNA levels were
available in 91% of TCEs during the 8 to 16 week window
following the change in therapy, in 83% of TCEs during the
16 to 36 week window, and in 58% of TCEs during the 36
to 52 week window. Two or more plasma HIV-1 RNA
levels were available in 49% of TCEs following the change
in therapy during the 8 to 16 week window, in 37% of TCEs
during the 16 to 36 week window, and in 17% of TCEs
during the 36 to 48 week windows.
Of the TCEs for which two or more plasma HIV-1 RNA
levels were available during the 16 to 36 week windowTable 1 Antiretrovirals (ARVs) Used For Salvage Therapy
in the 1,527 Treatment Chance Episodes (TCEs) *
ARV Class PIs†} NNRTIs NRTIs Other
ARVs LPV/r (401) EFV (399) 3TC (654) RAL (104)
FPV/r (187) NVP (164) TDF (604) MVC (22)
SQVr (158) ETR (28) d4T (587) ENF (48)
IDV/r (129) DLV (15) ddI (511)
ATV/r (120) ABC (435)
NFV (100) AZT (260)
DRV/r (81) FTC (185)
TPV/r (27)
Total 1,203 606 3,236 174
*The number within parenthesis following an individual ARV indicates the
number of TCEs in which the ARV was included in the salvage therapy
regimen.
† “/r” indicates ritonavir-boosting.
}Included among the 187 TCEs listed as having received FPV/r are 76 who
received unboosted FPV or APV; Included among the 158 TCEs listed as having
received SQV/r are 23 who received unboosted SQV; Included among the 129
TCEs listed as having received IDV/r are 34 who received unboosted IDV;
Included among the 120 TCEs listed as having received ATV/r are 4 who
received unboosted ATV.
Abbreviations: PI protease inhibitor; NRTI nucleoside RT inhibitor; NNRTI
non-nucleoside RT inhibitor; LPV lopinavir; FPV fosamprenavir; SQV saquinavir;
IDV indinavir; ATV atazanavir; NFV nelfinavir; DRV darunavir; TPV tipranavir; EFV
efavirenz; NVP nevirapine; ETR etravirine; DLV delavirdine; 3TC lamivudine; TDF
tenofovir; d4T stavudine; ddI didanosine; ABC abacavir; AZT zidovudine; FTC
emtricitabine; RAL raltegravir; MVC maraviroc; ENF enfuvirtide.
Fewer than 10 individuals received a double-boosted PI either as part of a
Type 1 or Type 2 Regimen. The PI component in these individuals was
denoted here as PI/r.
To avoid subdividing the Type 2 Regimens into too many small categories, no
distinction was made based on the number of NRTIs in the regimen.
Abbreviations: NRTIs nucleoside RT inhibitors, NNRTIs non-nucleoside RT
inhibitors, PIs protease inhibitors, PI/r ritonavir-boosted PIs.(n=562), there was a significant increase over time in the
proportion of TCEs for which two or more consecutive
plasma HIV-1 RNA levels were below the level of quantifi-
cation: 24% of the 140 TCEs occurring between 1998 and
1999, 38% of 186 TCEs occurring between 2000 and 2001,
50% of 139 TCEs occurring between 2002 and 2004, 69% of
97 TCEs occurring between 2005 and 2010 (OR: 1.3;
p< 0.0001).
The TCE XML documents have been placed in a publicly
available repository found on the following web page: http://
hivdb.stanford.edu/TCEs/. The TCE Repository contains
three primary functions. First, users can employ the TCE
Finder to identify TCEs matching specific criteria (Figure 1)
and examine the virological responses associated with the
TCEs. Second, users can obtain a graphical depiction of their
own TCEs by submitting a TCE XML document to the TCE
Viewer (Figure 2). Third, users can download the entire set
of TCE XML documents in a compressed file format or
browse eachTCE document using the TCE Viewer.
A B
Figure 1 Treatment-Change Episode (TCE) Finder. TCE Finder user interface including the input form (A) and output showing the summary of
the TCEs matching the input criteria (B). The example shown here is searching TCEs containing DRV/r and RAL in the salvage regimen. Fifty-seven
TCEs that met the input criteria were retrieved and the first five are shown in (A). For each TCE retrieved, the output table contains the following
fields: ARVs received prior to baseline, genotypic resistance test results at baseline, plasma HIV-1 RNA levels obtained following the change in
therapy, and a thumbnail image of each TCE that links to the graphical depiction of the TCE created by the TCE viewer. The graphical depiction
of the last TCE in the output is shown in Figure 2.
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insights from the TCE repository
One of the most pressing clinical challenges in resource-lim-
ited settings is the design of salvage therapy strategies for
patients developing virological failure following an initial
NRTI/NNRTI-containing regimen or, less commonly, an ini-
tial NRTI/PI-containing regimen. Figure 3A illustrates that
the TCE XML Repository contains 111 NRTI/NNRTI-
experienced but PI-naïve patients who received salvage ther-
apy with a ritonavir-boosted PI and an optimized NRTI
backbone. Figure 3B illustrates that the Repository contains
144 NRTI/PI-experienced but NNRTI-naïve patients who
received salvage therapy with an NNRTI and an optimized
NRTI backbone.
The proportion of patients attaining virological suppression
(<50 copies/ml) in the first 6 to 12 months of therapy was
significantly higher in those receiving salvage therapy with a
boosted PI (88/111, 79%) compared with an NNRTI (66/144,
46%; p< 0.001). The drug class used for salvage therapy
(boosted PI vs. NNRTI) remained significant in a multivariate
analysis that controlled for baseline CD4 count, plasma HIV-
1 RNA level, calendar year, and the expected activity of the
optimized NRTI backbone (i.e., the NRTI genotypic suscep-
tibility score, GSS). Among those receiving boosted PIs, the
proportions of responders were similar in those receivingatazanavir (26/33, 79%) compared with lopinavir (41/50,
82%). However, the mean baseline CD4 count was higher
(343 vs. 263) and the mean baseline plasma HIV-1 RNA
level was lower (3.9 vs. 4.2 log copies/ml) in those receiving
atazanavir. Among those receiving NNRTIs, the propor-
tions of responders were similar in those receiving efavirenz
(52/108, 48%) compared with nevirapine (14/36, 39%). The
mean baseline CD4 count and plasma HIV-1 RNA level
were also similar in those receiving efavirenz compared with
nevirapine (323 vs. 310; 4.1 vs. 4.2 log copies/ml).
However, in the pooled analyses of the 144 NNRTI-naïve
patients receiving an NNRTI, the number of NRTIs included
in the optimized backbone was significantly associated with
virological suppression: 27 of 44 patients (61%) who received
three or four NRTIs attained virological suppression com-
pared with 39 of 100 patients (39%) who received two NRTIs
(p=0.02; chi-square test). Neither the number of NRTIs nor
the NRTI GSS was significantly associated with response to
the PI-naïve patients receiving a boosted PI and an opti-
mized NRTI backbone.
Discussion
The Department of Human Health Services (DHHS) and
the WHO [10] have guidelines on which ARV regimens to
use for initial and second-line therapy of HIV-1-infected
CD4 Nadir: 20








3TC/AZT, IDV 19 4 4 4 3 4 181
D4T, NVP, NFV 5 4 3 4 5 195
D4T/DDI, NFV/SQV 14 4 4 144
3TC/ABC/D4T 32 2 2 3 4 4 209
3TC/TDF, LPVr/SQV 23 4 2 0 0 3 317
3TC/TDF, ATVr 20 5 3 2 2 3 5 2 0 137
Time-point Gene Mutations
1 PR 10I, 34Q, 43T, 54A, 63P, 71V, 82A, 92K
1 RT 20R, 35T, 39A, 41L, 67N, 70R, 101E, 103KN, 122E, 166R, 181C, 207E, 215Y, 219Q
2 PR 10I, 34Q, 43T, 54A, 63P, 71V, 82A, 92K
2 RT 20R, 35T, 39A, 41L, 67N, 70R, 101E, 103KN, 122E, 166R, 181C, 207E, 215Y, 219Q, 228H
3 PR 63PS, 72IT
3 RT 20R, 35T, 39A, 41L, 44ED, 60I, 67N, 70R, 101KE, 118VI, 122E, 166R, 181YC, 184V, 190A, 203EK, 207E, 208HY,
210SW, 215Y, 218DE, 219Q, 228H, 242QH
4 PR 10I, 24LI, 33LF, 34EQ, 43KT, 53FL, 54AV, 63P, 71V, 73S, 82AT, 92QK
4 RT 20R, 21VI, 35T, 39A, 41L, 67DN, 70KR, 122E, 166R, 184V, 207E, 215Y, 241VI
5 PR 10I, 13V, 33F, 34Q, 43T, 53L, 54A, 63P, 66F, 71V, 73S, 82A, 92K
5 RT 20R, 35T, 39A, 41L, 67N, 70S, 122E, 166R, 184V, 207E, 215Y
Figure 2 Treatment-Change Episode (TCE) Viewer. TCE Viewer plots (i) antiretroviral (ARV) regimens, plasma HIV-1 RNA levels, and CD4 counts
surrounding a treatment change (upper right); (ii) genotypic resistance test results (bottom); and (iii) a summary of the past ARV history (upper
left). ARVs are shown beneath the TCE timeline; plasma HIV-1 RNA levels in log copies/ml are shown in red; and CD4 counts are shown in blue.
Plasma HIV-1 RNA levels below the limits of quantification are indicated by inverted triangles. Genotype times are indicated by numbered vertical
dotted lines. Genotypic resistance test results list amino acid differences from the consensus B protease and RT sequences. Nucleoside-,
nonnucleoside, and protease inhibitor resistance mutations are colored. The past history summary shows the CD4 nadir and a list of past ARV
regimens. For each past regimen, the plasma HIV-1 RNA levels rounded to the nearest log10 value and the last CD4 count are shown.
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addressed by these guidelines including the management of
(i) patients who began ARV therapy with suboptimal regi-
mens – a problem particularly common in the U.S., Europe
in the past, and many middle income countries where pre-
viously available ARVs were considerably less potent and
drugs were used as they became available rather than as
part of a national treatment program, (ii) patients with
transmitted resistance, and (iii) heavily treated patients and
patients whose viruses have complex patterns of drug-re-
sistance mutations.
The difficulty of recommending therapy for such patients
has motivated researchers to study how pre-treatment
characteristics influence the response to a change in ARVtherapy. Indeed, there have been many studies correlating
the presence of baseline ARV-resistance mutations with
the response to a new ARV regimen while accounting for
essential covariates such as past treatment history, baseline
plasma HIV-1 RNA levels, and baseline CD4+ counts. Such
studies, however, often differ in their inclusion criteria (i.e.
past ARV treatments, timing of plasma HIV-1 RNA levels
and genotypic resistance data), salvage therapy require-
ments [11-18], and definition of virological response. For
example, some studies define virological response by the
extent of reduction in plasma HIV-1 RNA levels, whereas
others define it as the suppression of plasma HIV-1 RNA
levels below the limits of quantification [19,20]. Most of
studies have examined plasma HIV-1 RNA levels at fixed
Figure 3 Treatment change episodes (TCEs) of (A) PI-naïve and NRTI/NNRTI-experienced patients receiving a new regimen containing a
ritonavir-boosted PI and (B) NNRTI-naïve and NRTI/PI-experienced patients receiving a new regimen containing an NNRTI. The flow
diagrams illustrate the process by which the patients meeting the selection criteria where extracted from the TCE Repository. To reflect the clinical
reality in resource limited settings, patients receiving an integrase inhibitor, fusion inhibitor, or maraviroc were excluded. The tables beneath the
flow diagrams contain the numbers of patients (n) according to the specific PI/r (A) or NNRTI (B) and the proportions with virological suppression
to <50 copies/ml within 48 weeks (virological response; VR). The NRTI GSS was derived using the Stanford HIVdb algorithm (http://hivdb.stanford.
edu; accessed January 25, 2012). Abbreviations: PI - protease inhibitor; PI/r - ritonavir-boosted PI; NRTI - nucleoside RT inhibitor; NNRTI -
non-nucleoside RT inhibitor; LPV - lopinavir; FPV - fosamprenavir; SQV - saquinavir; IDV - indinavir; ATV - atazanavir; DRV - darunavir; EFV - efavirenz;
NVP – nevirapine.
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logical failure has been recently proposed [21].
A standardized representation of data such as that
found in the TCE XML Schema makes it possible to
apply uniform inclusion and virological endpoint criteria
across TCEs from different studies. The combined data
can be analyzed for three purposes (i) to reproduce prior
results, (ii) to apply and test new analytic methods, and
(iii) to generate or test new hypotheses. Many tools are
available to validate and transform the contents of XML
Schema documents. XML Schemas therefore ensure that
the data are represented consistently and can be readily
integrated into different applications.Studies of TCEs typically do not analyze the complete
treatment history of a patient. Rather these studies
parameterize essential features of the patient’s past ARV
exposures. This condensed treatment history combined
with the response to a new therapy was called a “treatment-
change episode” (TCE) by Larder et al. of the Resistance
Database Initiative (RDI) [22]. The TCE XML Schema is
therefore much less complex than the relational database
implemented by the HIV Cohort Data Exchange Protocol
(HICDEP) [23]. Moreover, the fact that the TCE XML
Schema does not require demographic or epidemiologic
data and allows relative (rather than absolute) dates makes
it impossible to identify individual patients or clinics [24].
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ics tools: (1) The XML Schema; (2) The TCE Viewer, an
online program that creates a graphical representation of
data in the XML document; (3) The TCE Repository,
which provides the proof-of-concept that the TCE XML
Schema can be used to exchange data from multiple
clinics; and (4) The TCE Finder, a search engine to iden-
tify TCEs meeting specific criteria. The TCE XML suite
is useful for comparing genotypic resistance interpreta-
tions and hypothesis generation and testing. It should
therefore be distinguished from ongoing projects
designed to optimize therapy for individual patients such
as RDI’s HIV Treatment Response Prediction System
(TREPS) [22] and Genafor’s Theo [25]. However, because
the data in the TCE Repository is publicly available it can
be used to increase the training sets for machine learning
systems such as Theo and TREPS.
Despite its nascent stage, the TCE Repository has already
been shown to be useful for comparing different genotypic
resistance test interpretation systems. Specifically, 734 of
the TCEs were previously used in a study comparing the
predictive value of three algorithms [26]. Without such a
repository, comparisons of genotypic resistance interpret-
ation systems can be performed solely by using proprietary
datasets. In addition, we demonstrate here that the TCE
Repository makes it possible to generate novel hypotheses
that that may be relevant to salvage therapy in resource-
limited regions. Indeed, at least one other research team
has proposed the use of three rather than two NRTIs for
certain salvage therapy scenarios in regions without access
to newer ARV classes [27]. However, considering the large
number of covariates associate with treatment response,
very large numbers of TCEs will be required to adequately
test novel hypotheses.
Although the XML Schema and Viewer are useful to
individual research groups and collaborations, the useful-
ness of the Finder and Repository depends on the will-
ingness of researchers to contribute data to this effort.
Therefore, we have collaborated with four research
groups to demonstrate the utility of the XML suite of
applications for collaboration between multiple clinics.
We are continuing to work with clinics in North Amer-
ica, Spain, and the EuResist Network Database to expand
the Repository with TCEs that are relevant to resource
limited regions (i.e. the regimens are confined primarily
to NRTI, NNRTIs, and PIs) and with TCEs involving the
use of more recently approved ARV classes including the
integrase inhibitors and maraviroc.
Conclusions
The TCE Suite of applications – the XML Schema,
Viewer, Finder, and Repository – addresses several major
needs in the analysis of predictors of virological response
to ARV therapy. The TCE XML Schema facilitates datasharing for generating and testing new hypotheses. The
TCE Viewer helps users validate the temporal relation-
ship between different data elements and it can be a use-
ful teaching tool. The TCE Finder is an application
designed for researchers who do not want to download
the entire TCE repository but who would rather examine
the solely the clinical data of patients sharing similar
ARV treatment and genotypic resistance characteristics.
The TCE Repository is the largest collection of publicly
available TCEs. It is already useful for comparing the
predictive value of genotypic resistance interpretation
systems. As it increases in size it will become an increas-
ingly useful resource for hypothesis generation and
knowledge discovery.
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